Therapeutic Class Report Overview : Hepatitis C Virus Infection

  • The launch of Protease inhibitors’ (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations have raised the bar and the expectations of pts, physicians and investors. Freedom from IFN, treating all genotypes and betting on vaccines could bring a sea of change in the HCV therapy class area in the future.

    Roche set the trend with the acquisition of Anadys for total of $230m followed by GILD buying VRUS for $11b, Bristol-Myers Squibb (BMY) acquired Inhibitex for $2.5b, VRTX acquired Virochem in 2009 for $375m + in-licensed Alios’ VX-135 in 2012 for total of $775m, and Abbott in-licensed Enanta’s ABT-450 for total of ~$310m. In the next spurt of M&A in this sector, we expect companies which offer differentiated MOA to be in the limelight, are (i) Alleviate the need for Ribavarin, (ii) Address resistance, non-responders, Liver cirrhosis, HIV-HCV –co infection etc, (iii) Target other genotypes, and (iv) Vaccines or Boosters of immune system (toll like receptors). In this report, we have analyzed the novel pipeline candidates, which target unmet needs, offer promise of an ‘all oral IFN-free treatment’ with at par or better efficacy / compliance, and novel vaccine candidates.

     

  • With tables and figures helping analyze worldwide Therapeutic Class market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

    The launch of Protease inhibitors’ (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations have raised the bar and the expectations of pts, physicians and investors. Freedom from IFN, treating all genotypes and betting on vaccines could bring a sea of change in the HCV therapy class area in the future.
    Roche set the trend with the acquisition of Anadys for total of $230m followed by GILD buying VRUS for $11b, Bristol-Myers Squibb (BMY) acquired Inhibitex for $2.5b, VRTX acquired Virochem in 2009 for $375m + in-licensed Alios’ VX-135 in 2012 for total of $775m, and Abbott in-licensed Enanta’s ABT-450 for total of ~$310m. In the next spurt of M&A in this sector, we expect companies which offer differentiated MOA to be in the limelight, are (i) Alleviate the need for Ribavarin, (ii) Address resistance, non-responders, Liver cirrhosis, HIV-HCV –co infection etc, (iii) Target other genotypes, and (iv) Vaccines or Boosters of immune system (toll like receptors). In this report, we have analyzed the novel pipeline candidates, which target unmet needs, offer promise of an ‘all oral IFN-free treatment’ with at par or better efficacy / compliance, and novel vaccine candidates.

     

  • The Therapeutic Class Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.

    Report Objectives / Segmentation Covered :
    By Companies / players:
      By Regions:
        By Type:
          By Application:
          Licensing options
          1000
          USD

          Need assistance ?

          Research objectives

          Where will all these developments take the industry in the long

          To study and analyze the global Market consumption (value & volume) by key regions/countries, product type and application, history data from 2015 to 2019, and forecast to 2025.

          What are the future opportunities in the market?

          To understand the structure of Market by identifying its various subsegments.

          What are the major driving forces expected to impact the development of the market market across different regions?

          To analyze the market with respect to individual growth trends, future prospects, and their contribution to the total market.

          Which industry trends are likely to shape the future of the industry during the forecast period 2020-2025?

          To project the consumption of market submarkets, with respect to key regions.

          Who are the major driving forces expected to decide the fate of the industry worldwide.

          To strategically profile the key players and comprehensively analyze their growth strategies.

          What are the key barriers and threats believed to hinder the development of the industry?

          To analyze competitive developments such as expansions,agreements, new product launches, and acquisitions in the market.

          Who are the prominent market players making a mark in the market with their winning strategies?

          To share detailed information about the key factors influencing the growth of the market

          What will be the growth rate and the market size of the industry for the forecast period 2020-2025?

          Focuses on the key global market Vendors, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

          Our Clients